Archer Investment Corp Acquires 4,400 Shares of Pfizer Inc. (NYSE:PFE)

Archer Investment Corp grew its holdings in Pfizer Inc. (NYSE:PFE) by 8.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 56,468 shares of the biopharmaceutical company’s stock after purchasing an additional 4,400 shares during the quarter. Archer Investment Corp’s holdings in Pfizer were worth $1,626,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Worth Asset Management LLC bought a new position in shares of Pfizer in the 1st quarter valued at about $29,000. Briaud Financial Planning Inc bought a new position in shares of Pfizer in the 3rd quarter valued at about $30,000. Sanctuary Wealth Management L.L.C. bought a new position in Pfizer during the 4th quarter worth approximately $50,000. Mizuho Securities Co. Ltd. bought a new position in Pfizer during the 3rd quarter worth approximately $34,000. Finally, VisionPoint Advisory Group LLC boosted its stake in Pfizer by 52,350.0% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 1,047 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently weighed in on the stock. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research note on Monday. TD Cowen lowered shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective on the stock. in a research note on Thursday, January 4th. Guggenheim assumed coverage on shares of Pfizer in a research note on Friday, February 23rd. They issued a “buy” rating and a $36.00 price target on the stock. Finally, Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Twelve equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $36.88.

Pfizer Stock Performance

NYSE PFE traded down $0.25 on Wednesday, hitting $25.44. 33,630,497 shares of the stock were exchanged, compared to its average volume of 42,423,824. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69. The business’s fifty day moving average is $27.23 and its 200 day moving average is $28.79. Pfizer Inc. has a 52 week low of $25.26 and a 52 week high of $41.33. The company has a market capitalization of $144.06 billion, a PE ratio of 71.36, a P/E/G ratio of 1.18 and a beta of 0.61.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.29. The company had revenue of $14.25 billion for the quarter, compared to analyst estimates of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The company’s revenue was down 41.3% on a year-over-year basis. During the same period in the prior year, the firm earned $1.14 earnings per share. Research analysts anticipate that Pfizer Inc. will post 2.22 EPS for the current fiscal year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.